Friday, 21 February 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 21 February 2025
News

Trial astounds in blood cancer

Posted 18 February 2025 PM

More than half the patients enrolled in a Phase 1b trial of a combination treatment for people who have failed multiple lines of therapy for a blood cancer have achieved a complete response.

Sydney-based Imugene is running the trial of its off-the-shelf CAR T therapy azercabtagene zapreleucel (azer-cel) in combination with chemotherapy and interleukin 2 in treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL), in which four out of the seven enrolled have achieved a complete response.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (24)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (2)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.